Description

Irinotecan Hydrochloride 100 mg/5 ml, Solution for Injection

Irinotecan hydrochloride is an antineoplastic cytotoxic medicinal product belonging to the group of topoisomerase I inhibitors, widely used in oncology as part of chemotherapy regimens. The medicine is intended for the treatment of malignant tumors and is administered strictly under the supervision of a medical specialist.

The product is supplied as a solution for injection and is intended for intravenous administration after appropriate dilution. It is used primarily in hospital settings under continuous medical monitoring.

⭐ Key Product Information

✔ Dosage form: solution for injection
✔ Active ingredient: irinotecan hydrochloride
✔ Strength / concentration: 100 mg / 5 ml
✔ Pharmacological group: topoisomerase I inhibitors
✔ Category: antineoplastic (cytotoxic) medicines
✔ Prescription status: prescription-only
✔ Use: strictly as prescribed by a physician

⭐ Use in Clinical Practice

Irinotecan is used as monotherapy or as part of combination chemotherapy regimens for the treatment of:

✔ colorectal cancer (including metastatic disease)
✔ other solid tumors, according to approved treatment protocols
✔ cases where previous anticancer therapy has not produced an adequate clinical response

🟦 Malignant diseases are characterized by uncontrolled proliferation of tumor cells, which requires specialized systemic anticancer therapy.

⭐ Mechanism of Action

Irinotecan is a prodrug that is metabolized in the body to its active metabolite SN-38.
SN-38 inhibits the enzyme DNA topoisomerase I, which is essential for DNA replication and repair in dividing cells.

As a result of this mechanism:

✔ DNA replication is disrupted
✔ single-strand DNA breaks accumulate
✔ tumor cell division is inhibited
✔ apoptotic pathways are activated, leading to tumor cell death

The medicine is particularly active against rapidly dividing cancer cells.

❗ Important Information

The decision to initiate treatment with irinotecan is made exclusively by the treating oncologist, taking into account the diagnosis, disease stage, patient’s overall condition, and selected chemotherapy regimen.

⭐ Precautions and Medical Monitoring

❗ Before starting therapy, patients should inform their physician if they have:

• hypersensitivity to irinotecan or other medicinal products
• impaired liver or kidney function
• bone marrow suppression or hematological disorders
• active infections or immunodeficiency conditions
• severe adverse reactions to previous chemotherapy

Regular laboratory monitoring and clinical assessment are required during treatment.

⭐ Additional Information

🔹 The medicine is prescription-only
🔹 Used primarily in hospital settings
🔹 Administered under the supervision of an oncologist
🔹 Information provided is for reference purposes only
🔹 Not a substitute for professional medical advice